Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
ATCC ATCC LAMA84-r (CRL-3348) human CML suspension cell line, imatinib-resistant - 8.0x10^6-1.0x10^7 cells/vial
Supplier: ATCC CRL3348
LAMA84-r (ATCC CRL-3348) is a human chronic myeloid leukemia (CML)-derived suspension cell line resistant to imatinib. Paired with an imatinib-sensitive clone, it is used to study sensitivity and resistance to BCR-ABL-targeted therapies.
- Human hematopoietic suspension cell line derived from CML in blast crisis.
- Resistant to imatinib mesylate; paired with an imatinib-sensitive clone for comparison.
- Approximately 8.0 x 10^6 to 1.0 x 10^7 cells per vial; vial volume 1.0 mL.
- Viability ≥ 50% on arrival; store frozen in liquid nitrogen vapor.
- Maintain cultures at 3 x 10^5 to 1 x 10^6 viable cells/mL; renew medium every 2-3 days.
- Recommended base medium: RPMI-1640 supplemented with fetal bovine serum, L-glutamine, and 1 μM imatinib working stock.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?